EU-X-CT Public Stakeholder Conference 2025
Making cross-border access to clinical trials a reality
The pan-European public-private EU-X-CT Initiative aims at facilitating cross-border access to clinical trials in concrete terms. Over the past 2 years we have collected information from multiple stakeholders on the regulatory, ethical, social security and organizational conditions, experiences, and best practices for cross-border access to trials in many European countries. The data has been used to populate a publicly accessible EU-X-CT website and to draft recommendations on various aspects of cross-border trials, which were published for public consultation in Feb 2025. At this conference we will present the consolidated recommendations and align with interested stakeholders and policy makers on how to translate them into a clear and simple pathway for patients to access a trial in another European country.
Join us online!
This conference will be available to attend remotely via Zoom, click here to register and attend online.
Online attendance is free, but there will be no possibilities for the online attendants to interact with participants or speakers in the room. The conference will be in "view only".
With the Support of
Programme
| 9:00 |
Registration and welcome coffee |
| 9:30 |
Welcome and introduction to EU-X-CT
Ingrid Klingmann, European Forum for Good Clinical Practice
Susan Bhatti, Merck BV, European Federation of Pharmaceutical Industries Associations
|
|
Keynote Address – European Institutions
Isabelle Clamou, DG Sante EU Commission
Kasia Jurczak, DG R&I EU Commission
Tomislav Sokol, Member of the European Parliament
|
|
|
Session 1: EU-X-CT achievements and best practice examples |
|
| 10:15 |
EU-X-CT Recommendations Moderator(s): Ingrid Klingmann, European Forum for Good Clinical Practice Susan Bhatti, Merck BV, European Federation of Pharmaceutical Industries Associations
Ana Zanoletty, European Medicines Agency
Emilie Prazakova, Roche
Lisbeth Oxholm Snede, PiCC United
Marianne Lunzer, AGES, Clinical Trials Coordination Group
Monique Al, CCMO, Clinical Trials Coordination Group, MedEthicsEU
|
| 11:20 |
Introduction to the EU-X-CT website
Bryan Michaux, European Forum for Good Clinical Practice
|
| 11:30 |
Coffee break |
| 11:45 |
National/regional initiatives enabling cross-border options Moderator(s): Emilie Prazakova, Roche
Clara Boyer, Centre Léon Bérard
Marianne Pilgaard, Trial Nation
Ricardo Fernandes, conect4children
Sónia Carvalho, Agency for Clinical Research and Biomedical Innovation
|
| 12:45 |
Lunch |
|
Session 2: Key issues to be addressed to facilitate cross-border trial access |
|
| 13:45 |
Where to go from here?
Ingrid Klingmann, European Forum for Good Clinical Practice
|
| 13:55 |
Challenges and options for cross-border trial participation: Health insurance, language, liability insurance Moderator(s): Ingrid Klingmann, European Forum for Good Clinical Practice
Begonya Nafria Escalera, Head of Patient Engagement in Research- SJD Barcelona Children’s Hospital
Jana Hlaváčová, Ministry of Health Czechia
Michał Dybowski, Foundation Healthcare Poland
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, CZ Health Insurance
|
| 15:00 |
Coffee break |
|
Session 3: Where do we want to go? (Sustainability + Impact + Usability)
Enabling improvements on national levels |
|
| 15:15 |
Panel discussion: enabling options for cross-border trial access in Europe Moderator(s): Daria Julkowska, European Rare Diseases Research Alliance
Begonya Nafria Escalera, Head of Patient Engagement in Research- SJD Barcelona Children’s Hospital
Magda Chlebus, European Federation of Pharmaceutical Industries Associations
Marianne Lunzer, AGES, Clinical Trials Coordination Group
Monique Al, CCMO, Clinical Trials Coordination Group, MedEthicsEU
|
| 16:15 |
Sustainability and Implementation aspects
e.g. European Partnership programmes and other options (Biotech Act)
Moderator(s): Ingrid Klingmann, European Forum for Good Clinical Practice
Angela Strambi, Fondazione Toscana Life Sciences
Francois Houÿez, EURORDIS
Isabella Clamou, DG Sante EU Commission
Magda Chlebus, European Federation of Pharmaceutical Industries Associations
|
| 16:45 |
Conclusions and next steps
Ingrid Klingmann, European Forum for Good Clinical Practice
Susan Bhatti, Merck BV, European Federation of Pharmaceutical Industries Associations
|
| 17:00 |
End of meeting |